● Defense WorldNov 14, 2026 · 04:42 ETEARNINGS EXPECTED BY FEB 2
AbbVie Inc. $ABBV Stock Sold by BCV Asset Management Inc.
BCV Asset Management Inc. trimmed its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 2.2% during a recent quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SE…
● Defense WorldNov 10, 2026 · 03:53 ETEARNINGS EXPECTED BY FEB 2
AbbVie Inc. $ABBV Stock Bought by AlphaCore Capital LLC
AlphaCore Capital LLC grew its stake in AbbVie Inc. (NYSE: ABBV) by 11.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor ow…
● Defense WorldNov 9, 2026 · 04:03 ETEARNINGS EXPECTED BY FEB 2
CenterBook Partners LP Purchases New Stake in AbbVie Inc. $ABBV
CenterBook Partners LP acquired a new stake in AbbVie Inc. (NYSE: ABBV) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 7,216 shares o…
As tech stocks retreat, AbbVie (ABBV) and Eli Lilly (LLY) are hitting fresh 52-week highs, offering investors defensive healthcare exposure with compelling growth potential.…
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.…
● 24/7 Wall StreetNov 3, 2026 · 11:03 ETEARNINGS EXPECTED BY FEB 2
AbbVie Hit a New High After Earnings. There's More Upside Left.
AbbVie just logged a 33% gain for the year and raised its guidance again, but the real question is whether Skyrizi and a newly closed pipeline deal can push shares even further past a valuation that already looks stretch…
Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
– Nine abstracts will be presented, including new data from Phase 4 research examining aesthetic treatment following medical weight loss, with a focus on patient satisfaction and psychosocial outcomes – A digital image a…
Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, an Increase of Over 100.0 Percent; These Results Include an Unfavorable Impact of $0.11 Per Sh…
● PRNewsWireOct 27, 2026 · 08:00 ETCOMPANY'S OWN WORDS
AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma
– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings, including in commu…
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 AFF…
● PRNewsWireOct 22, 2026 · 09:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 2
AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked secondary endpoints, includin…
Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence
Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM ® , SKINVIVE™ and BOTOX ® Cosmetic The latest HArmonyCa™ data reinforces its dual-action technolo…
Article counts from the last market-wide feed page, across every symbol we track and not just ABBV · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.